Skip to Content
Epizyme Logo
Contact

Site - Header Menu

  • About
    • Mission & Vision
    • Management Team
    • Board of Directors
    • Collaborations & Partnerships
  • Science
    • Epigenetic Scientific Platform
    • Preclinical Discovery Programs
    • Publications & Presentations
  • Clinical Development
    • Clinical Programs
    • Clinical Trials
    • Expanded Access Policy
    • Investigator Sponsored Trials
    • Medical Education & Sponsorship
  • Medicines
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Information
      • SEC Filings
      • Quarterly Results
      • Annual Report & Proxy
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Analyst Coverage
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Corporate Governance Documents
    • Resources
  • Careers

Investors & Media

Site - Investor Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Report & Proxy
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Corporate Governance Documents
  • Resources
    • Investor FAQs
    • Contact

Press Releases

Press Releases

Date Title Views
Jun 27, 2022 Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
PDF Version
View HTML
Jun 02, 2022 Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
PDF Version
View HTML
May 17, 2022 Epizyme To Participate in H.C. Wainwright Global Investment Conference
PDF Version
View HTML
May 10, 2022 Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
PDF Version
View HTML
May 03, 2022 Epizyme Announces Date of First Quarter 2022 Financial Results
PDF Version
View HTML
Apr 06, 2022 Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version
View HTML
Mar 15, 2022 Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
PDF Version
View HTML
Mar 02, 2022 Epizyme to Participate in Upcoming Healthcare Conferences in March
PDF Version
View HTML
Mar 01, 2022 Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
PDF Version
View HTML
Feb 22, 2022 Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
PDF Version
View HTML

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Site - Investor Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Report & Proxy
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Analyst Coverage
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Corporate Governance Documents
  • Resources
    • Investor FAQs
    • Contact

Site - Shareholder Tools

Print Page
Email Alerts
  • Home
  • Privacy Policy
  • Terms of Use
  • Site Map
  • Contact
© 2022 Epizyme, Inc. - All Rights Reserved
▲